Our
Pipeline
Our Pipeline Includes Potential First- Or
Best-In-Class Molecules
Cullinan Oncology has built a diversified pipeline by identifying high-impact targets first and then pursuing the right modality. The pipeline contains assets that activate the immune system or inhibit key oncogenic drivers across a wide range of modalities, each with the potential to be best- or first-in-class.
Programs Spanning A Range Of Indications And Platforms.
Our Differentiated Oncology Assets
By identifying high-impact targets, then pursuing the right modality, we've built a diversified pipeline of assets ranging from engineered proteins to monoclonal antibodies, as well as kinase inhibitors and protein degraders, each with the potential to be best or first in its class.
CLN-619
Anti-MICA/B IgG1
Phase 1
Pan-cancer
Status:
Monotherapy dose expansion, combo escalation ongoing
Zipalertinib (CLN-081/TAS6417)
EGFRex20ins inhibitor
Phase 2
NSCLC with exon 20 insertion mutations 2+ lineNSCLC with exon 20 insertion mutations frontline
Status:
Pivotal 2+ line and frontline studies actively enrolling
B7H4 x 41BB bispecific immune activator
Phase 1
Multiple solid tumors
Status:
Monotherapy dose escalation ongoing
CD19/CD3 T-cell antibody construct with HSA binding domain
Phase 1
B-cell NHL
Status:
Phase 1 study ongoing
Collagen-binding IL-12-IL2 fusion protein
IND-Enabling
Pan-cancer
Status:
FDA IND Clearance Received
Early Programs
Powered by our novel research model and with patient benefit as our priority, we innovate without borders, applying rigorous early experimentation to fast-track only the most promising assets to the clinic and ultimately commercialization. Early programs we're currently exploring include:
- T-cell Receptor (TCR) – TCR-based therapy targeting a senescence and cancer-related protein pMHC complex.
- HPK1 Targeting – A potential first-in-class protein degrader that acts as a negative regulator of T cells and TCR signaling.
Harnessing Science for Patient Benefit
Our clinical trials are designed with clinically relevant endpoints and predefined benchmarks for success.